Core Insights - Novo Nordisk announced new data on the cardiovascular protective benefits of Wegovy and Ozempic, to be presented at the ESC Congress 2025, highlighting the role of inflammation in atherosclerotic cardiovascular disease (ASCVD) [1][3] Group 1: Cardiovascular Benefits - Semaglutide has been shown to reduce the risk of cardiovascular events by 20-26%, leading to fewer hospitalizations, heart attacks, strokes, and deaths among individuals with diabetes and obesity [2] - Novo Nordisk will present data demonstrating the unique benefits of semaglutide on heart and kidney disease, supported by both clinical trials and real-world evidence [4][6] Group 2: Symposium and Presentations - A symposium on the role of cardiovascular inflammation in ASCVD will take place on August 30, with various presentations scheduled throughout the congress, focusing on the effects of semaglutide in different patient populations [3][7] - Key presentations will include the impact of Wegovy on atrial fibrillation in obese individuals and new cardiometabolic benefits of Rybelsus and Ozempic in type 2 diabetes patients [6][7] Group 3: Company Overview - Novo Nordisk is a leading global healthcare company focused on chronic diseases, employing approximately 78,400 people and marketing products in around 170 countries [13]
Novo Nordisk to present Wegovy® and Ozempic® data showing life-saving cardiovascular benefits for people living with obesity and type 2 diabetes at the European Society of Cardiology Congress 2025